論文

2012年8月

Tumor cell-specific prodrugs using arsonic acid-presenting iron oxide nanoparticles with high sensitivity

BIOORGANIC & MEDICINAL CHEMISTRY
  • Hiroki Minehara
  • ,
  • Asako Narita
  • ,
  • Kensuke Naka
  • ,
  • Kazuo Tanaka
  • ,
  • Moeko Chujo
  • ,
  • Masaya Nagao
  • ,
  • Yoshiki Chujo

20
15
開始ページ
4675
終了ページ
4679
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.bmc.2012.06.012
出版者・発行元
PERGAMON-ELSEVIER SCIENCE LTD

We report the tumor cell-selective prodrugs based on the arsonic acid-presenting iron oxide nanoparticles. We synthesized the well-dispersed nanoparticles having arsonoacetic acid which is composed of the low toxic As(V) form. From the analyses of the reaction products, it is suggested that the reduction by dithiothreitol with arsonoacetic acid and the modified nanoparticles could generate the highly-toxic As(III) species. In the MTT assays, it was found that the cell viabilities of HeLaS3 and especially HepG2 were reduced in the presence of the modified nanoparticles. In contrast, a slight effect on viability was observed with primary mouse hepatocytes. The viabilities showed good agreements with the amounts of intracellular reduced glutathione concentrations. Furthermore, the valid concentrations of the modified nanoparticles for tumor-specific cytotoxicity were similar level in MRI measurements. These results indicate that arsonic acid-presenting nanoparticles should be a good platform for developing highly-sensitive tumor-specific prodrugs. (C) 2012 Elsevier Ltd. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.bmc.2012.06.012
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000306480200009&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.bmc.2012.06.012
  • ISSN : 0968-0896
  • eISSN : 1464-3391
  • Web of Science ID : WOS:000306480200009

エクスポート
BibTeX RIS